RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance

Blood

Volumn 129, Issue 8, 2017, Pages 1045-1048

  Stegmann, Tamara C ^a   Veldhuisen, Barbera ^a,b   Nagelkerke, Sietse Q ^a,c   Winkelhorst, Dian ^a   Schonewille, Henk ^c   Verduin, Esther P ^c   Kuijpers, Taco W ^a,c   De Haas, Masja ^b,c,d   Vidarsson, Gestur ^a   Van Der Schoot, C Ellen ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; RHESUS ANTIBODY; ALLOANTIBODY; FC RECEPTOR; RHESUS D ANTIBODY;

ADAPTIVE IMMUNITY; ALLELE; ALLOIMMUNIZATION; CAUCASIAN; COPY NUMBER VARIATION; ERYTHROCYTE; FCGR 2 GENE; FCGR 3 GENE; GENE; GENETIC POLYMORPHISM; GENETIC VARIATION; HUMAN; IMMUNE RESPONSE; LETTER; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; BLOOD; BLOOD GROUP RHESUS SYSTEM; CASE CONTROL STUDY; FEMALE; GENE FREQUENCY; GENETICS; IMMUNOLOGY; MIDDLE AGED; NEWBORN; NEWBORN HEMOLYTIC DISEASE; TREATMENT FAILURE;

ADULT; CASE-CONTROL STUDIES; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTES; FEMALE; GENE FREQUENCY; HUMANS; INFANT, NEWBORN; ISOANTIBODIES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; RECEPTORS, IGG; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN; TREATMENT FAILURE;

EID: 85014958908     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-05-716365     Document Type: Letter

References (25)

1. de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109(2):99-113.
2. Koelewijn JM, de Haas M, Vrijkotte TG, Bonsel GJ, van der Schoot CE. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion. 2008;48(8):1721-1729.
3. Hidalgo C, Romano EL, Linares J, Suarez G. Complement fixation by Rh blood group antibodies. Transfusion. 1979;19(3):250-254.
4. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007;93(2):99-111.
5. Kumpel BM, Elson CJ. Mechanism of anti-D-mediated immune suppression-a paradox awaiting resolution? Trends Immunol. 2001;22(1):26-31.
6. Beliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol. 2008;141(1):109-119.
7. Kumpel BM, Goodrick MJ, Pamphilon DH, et al. Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers. Blood. 1995;86(5):1701-1709.
8. Kumpel BM, De Haas M, Koene HR, Van De Winkel JG, Goodrick MJ. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16). Clin Exp Immunol. 2003;132(1):81-86.
9. Stucki M, Schnorf J, Hustinx H, et al. Anti-D immunoglobulin in Rh(D) negative volunteers: clearance of Rh(D) positive red cells and kinetics of serum anti-D levels. Transfus Clin Biol. 1998;5(3):180-188.
10. Brinc D, Denomme GA, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? Curr Opin Hematol. 2009;16(6):488-496.
11. Li X, Gibson AW, Kimberly RP. Human FcR polymorphism and disease. Curr Top Microbiol Immunol. 2014;382:275-302.
12. Miescher S, Spycher MO, Amstutz H, et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood. 2004;103(11):4028-4035.
13. Breunis WB, van Mirre E, Bruin M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood. 2008;111(3):1029-1038.
14. van der Heijden J, Breunis WB, Geissler J, de Boer M, van den Berg TK, Kuijpers TW. Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J Immunol. 2012;188(3):1318-1324.
15. Tsang ASMW, Nagelkerke SQ, Bultink IE, et al. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford). 2016;55(5):939-948.
16. Verduin EP, Lindenburg IT, Smits-Wintjens VE, et al. Long-term follow up after intra-uterine transfusions; the LOTUS study. BMC Pregnancy Childbirth. 2010;10:77.
17. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109-1114.
18. Li X, Wu J, Ptacek T, et al. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med. 2013;5(216):216ra175.
19. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol. 2015;5:674.
20. Su K, Wu J, Edberg JC, et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J Immunol. 2004;172(11):7186-7191.
21. Tan JC, Armstrong NJ, Yuan FF, Flower RL, Dyer WB. Identification of genetic polymorphisms that predict responder/non-responder profiles to the RhD antigen. Mol Immunol. 2015;68(2 Pt C):628-633.
22. Yu H, Stowell SR, Bernardo L, et al. Antibody-mediated immune suppression of erythrocyte alloimmunization can occur independently from red cell clearance or epitope masking in a murine model. J Immunol. 2014;193(6):2902-2910.
23. Bernardo L, Amash A, Marjoram D, Lazarus AH. Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice. Blood. 2016;128(8):1076-1080.
24. Liu J, Santhanakrishnan M, Natarajan P, et al. Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood. 2016;128(26):3159-3168.
25. Stowell SR, Liepkalns JS, Hendrickson JE, et al. Antigen modulation confers protection to red blood cells from antibody through Fcγ receptor ligation. J Immunol. 2013;191(10):5013-5025.